Stephen J.LurieMD, PhD, Contributing EditorIndividualAuthor
Copyright 2000 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2000
To the Editor: The trial conducted by Dr Hjalmarson
and colleagues1 extends current knowledge
of the benefits of β-blockade in patients with CHF. The investigators
were able to titrate the dosage of metoprolol CR/XL to a mean of 159 mg/d,
approaching the target dosage of 200 mg/d. Eighty-nine percent of patients
in the metoprolol CR/XL group and 90% of those in the placebo group were receiving
angiotensin-converting enzyme (ACE) inhibitors, yet the mean dosages were
only moderate; for example, 14 mg/d of enalapril in each group at baseline.
Fontanarosa PB, Wiener DH. β-Blockade for Patients With Heart Failure. JAMA. 2000;284(4):436-437. doi:10.1001/jama.284.4.436